

Executive Corridor
Darlington Memorial Hospital
Hollyhurst Road
Darlington
DL3 6HX
Switchboard Tel: 01325 38 0100
Foundation Trust Office: 01325 74 3625
Corporate Records Office: 01325 74 3700

Request for Information Reference: 04.22.58

FOI Direct line: 01325 743700
Email: cdda-tr.cddftfoi@nhs.net

Email only

18th May 2022

Freedom of Information Act 2000 – Request for Information

Thank you for submitting a request for information which we received on 29th April 2022 in relation to County Durham and Darlington NHS Foundation Trust (the Trust). Your request has been processed under the provisions of the Freedom of Information Act 2000 and I am now able to provide you with a response.

Your request was in relation to treatment of CLL and MCL and I am providing the following information in response to your specific questions:

The data in questions 1-4 cover the time period from 1/02/2022 - 30/04/2022.

1. How many Chronic Lymphocytic Leukaemia (CLL) patients have been treated in the past 3 months with the following:

- **BR (bendamustine + rituximab) - 1**
- **Calquence (acalabrutinib) - 14**
- **FCR (fludarabine + cyclophosphamide + rituximab) - 0**
- **Gazyva (obinutuzumab) + chlorambucil - 1**
- **Imbruvica (ibrutinib) - 17**
- **Venclexta (venetoclax) - 20**
- **Venclexta (venetoclax) + Gazyva (obinutuzumab) - 8**
- **Venclexta (venetoclax) + rituximab - 0**
- **Zydelig (idelalisib) + rituximab - 1**
- **Any other systemic anti-cancer therapy - 1**

2. How many Mantle Cell Lymphoma (MCL) patients have been treated in the past 3 months with the following:

- **BR (bendamustine + rituximab) - 0**

- Imbruvica (ibrutinib) - 9
 - Imbruvica (ibrutinib) + rituximab - 0
 - R-BAC (rituximab, bendamustine and cytarabine) - 0
 - R-CHOP (rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone) - 2
 - Nordic Protocol (rituximab, cyclophosphamide, doxorubicin, vincristine, cytarabine & prednisolone) - 0
 - Velcade (bortezomib) + chemotherapy - 0
 - Any other systemic anti-cancer therapy - 11
 - Stem cell transplant - 0
 - Tecartus (CAR-T) - Autologous anti-CD19-transduced CD3+ cells - 0
3. How many Chronic Lymphocytic Leukaemia (CLL) patients have received first-line treatment in the past 3 months with the following:
- Calquence (acalabrutinib) - 0
 - Imbruvica (ibrutinib) - 0
 - Venclexta (venetoclax) + Gazyva (obinutuzumab) - 4
 - Zydelig (idelalisib) + rituximab - 0
4. How many Mantle Cell Lymphoma (MCL) patients have received first-line treatment in the past 3 months with the following:
- Imbruvica (ibrutinib) - interim COVID guideline - 0
 - Imbruvica (ibrutinib) + rituximab - 0
 - R-BAC (rituximab, bendamustine and cytarabine) - 0
 - R-CHOP (rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone) – 2
5. Does your trust currently participate in any ongoing clinical trials for the treatment of Chronic Lymphocytic Leukaemia (CLL)? If so, can you please provide the name of each trial along with the number of patients taking part?
- No
6. Does your trust currently participate in any ongoing clinical trials for the treatment of Mantle Cell Lymphoma (MCL)? If so, can you please provide the name of each trial along with the number of patients taking part?
- No

In line with the Information Commissioner's directive on the disclosure of information under the Freedom of Information Act 2000 your request will form part of our disclosure log on the Trust's website. However please be assured that we anonymise all responses prior to adding them to the disclosure log.

I hope that this response has provided you with the information you had requested. If you have any queries or wish to discuss the information supplied, please do not hesitate to contact me by telephone or in writing. If however, you are dissatisfied with the way in which your request has been handled and would like an internal review, you will need to contact me in writing at the above address or via cdda-tr.cddftfoi@nhs.

If you remain dissatisfied with our response following an internal review you have the right to appeal to The Information Commissioner at Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF. More information is available on their website; www.ico.gov.uk.

Yours sincerely

Corporate Records and Freedom of Information Facilitator